HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Birol Yamak S Fehmi Katircioglu Oguz Tademir Kemal Bayazit Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yamak, B. Articles by Bayazit, K. Search for Related Content PubMed Articles by Yamak, B. Articles by Bayazit, K.

Ten-Year Results With Liotta Porcine Bioprostheses in the Mitral Position

Birol Yamak, MD, Binali Mavita, MD, Ahmet Sarita, MD, S Fehmi Katircioglu, MD, A Tulga Ulus, MD, Levent Birincioglu, MD, Y Haldun Karagöz, MD¹, Erol Sener, MD, Oguz Tademir, MD, Kemal Bayazit, MD¹

Department of Cardiovascular Surgery Türkiye Yüksek I·htisas Hospital Ankara, Turkey 1 Güven Hospital Ankara, Turkey

For reprint information contact: Birol Yamak, MD Department of Cardiovascular Surgery Türkiye Yüksek I·htisas Hospital Sihhiye, Ankara 06100, Turkey Tel:90 312 310 3080 Ext. 1247 Fax:90 312 312 4120 Email: ulus{at}escortnet.com

The Liotta porcine bioprosthesis is a third generation bioprosthesis with a very low profile supraannular configuration with low-pressure glutaraldehyde-fixed tissue. Between May 1986 and December 1990, 670 patients underwent isolated mitral valve replacement with Liotta porcine bioprosthesis. There were 403 (60%) females and 267 (40%) males; the mean age was 39.03 ± 4.57 years (range, 16 to 75 years). The predominant lesion was combined mitral stenosis and mitral insufficiency in 46% of the patients. The operative mortality rate was 5.9% and the most frequent cause of the mortality was low cardiac output. Total follow-up was 3193.5 patient-years. The average follow-up period was 6.1 ± 2.5 years (range, 1 to 10 years). During the late period, 44 patients (1.4% per patient-year) died. The long-term survival estimate at 10 years was 84.8% ± 2.7%. Structural valve deterioration developed in 198 patients (6.2% per patient-year). Actuarial estimates of freedom from structural valve deterioration at 5 and 10 years were 87.6% ± 1.5% and 28.5% ± 4.5% and it was unrelated to sex or age. Most patients (88%) who developed bioprosthesis dysfunction underwent repeat valve replacement. The period between the implantation and development of structural valve deterioration was 5.9 ± 1.8 years for female patients and 6.2 ± 1.8 years for males (no statistically significant difference). We concluded from the early and high rates of structural valve deterioration in this young age group that the Liotta porcine bioprosthesis has limited long-term durability for mitral valve replacement.